SHANGHAI LABWAY CLINICAL LABORATORY CO., LTD

Shanghai Labway Clinical Laboratory Co., Ltd

Equities

301060

CNE100004RG8

Healthcare Facilities & Services

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
9.77 ^CNY	-0.20%		+8.19%	-26.49%

Apr. 26	Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023.	CI

Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023.

January 04, 2024 at 04:16 am EST

From November 11, 2023 to December 31, 2023, the company has repurchased 751,500 shares, representing 0.19% for CNY 10.25 million. With this, the company has completed the repurchase of 751,500 shares, representing 0.19% for CNY 10.25 million under the buyback announced on November 16, 2023.

Latest news about Shanghai Labway Clinical Laboratory Co., Ltd

Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023.	Apr. 01	CI
Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023.	Jan. 04	CI
Shanghai Labway Clinical Laboratory Co., Ltd announces an Equity Buyback for CNY 30 million worth of its shares.	Nov. 16	CI
Shanghai Labway Clinical Laboratory Co., Ltd authorizes a Buyback Plan.	Nov. 10	CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Certain A Shares of Shanghai Labway Clinical Laboratory Co., Ltd. are subject to a Lock-Up Agreement Ending on 14-SEP-2023.	23-09-13	CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Labway Clinical Laboratory to Buy Enterprise Management Firm For 283 Million Yuan	23-07-10	MT
Shanghai Labway Clinical Laboratory Co., Ltd Announces Final Cash Dividend on A Shares for the Year 2022, Payable on June 20, 2023	23-06-14	CI
Shanghai Labway Clinical Laboratory Co., Ltd Approves Cash Dividend for 2022	23-05-29	CI
Shanghai Labway Clinical Laboratory Co., Ltd Proposes Final Cash Dividend for the Year 2022	23-04-27	CI
Shanghai Labway Clinical Laboratory Co., Ltd cancelled the transaction announced on September 1, 2022	23-04-26	CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
As China seeks to live with the virus, COVID-control industries face decline	22-12-15	RE
Chinese COVID testing firms report big profits as virus fight intensifies	22-11-03	RE
Shanghai Labway Clinical Laboratory Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Shanghai Labway Clinical Laboratory Co., Ltd.(XSEC:301060) added to S&P Global BMI Index	22-09-19	CI
Certain A Shares of Shanghai Labway Clinical Laboratory Co., Ltd. are subject to a Lock-Up Agreement Ending on 14-SEP-2022.	22-09-13	CI
Shanghai Labway Plans $96 Million Share Sale to Fund New Laboratories	22-09-05	MT
Shanghai Labway Clinical Laboratory Co., Ltd. announced that it expects to receive CNY 664.4942 million in funding	22-08-31	CI
Shanghai Labway Clinical Laboratory Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Jiangsu Xikang Technology Co., Ltd. announced that it expects to receive CNY 140 million in funding from Shanghai Labway Clinical Laboratory Co., Ltd	22-08-23	CI

Chart Shanghai Labway Clinical Laboratory Co., Ltd

Duration

Period

Chart Shanghai Labway Clinical Laboratory Co., Ltd

More charts

Company Profile

Shanghai Labway Clinical Laboratory Co Ltd is a company providing overall solutions for the inspection and diagnosis industry. The Company's businesses include medical testing and pathological diagnosis services and the sales of in vitro diagnosis product. The medical examination and pathological diagnosis services include pathological diagnosis, molecular examination, biochemical examination, immune examination, microbial examination, clinical basic examination and physical and chemical examination. The in vitro diagnostic products sales include in vitro diagnostic instruments, reagents and related accessories and consumables.

Sector

Healthcare Facilities & Services

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
SHANGHAI LABWAY CLINICAL LABORATORY CO., LTD	-26.49%	540M
SONIC HEALTHCARE LIMITED	-17.89%	8.25B
RADNET, INC.	+39.20%	3.57B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.46B
SYNLAB AG	-8.06%	2.46B
DR. LAL PATHLABS LIMITED	-7.35%	2.38B
NEOGENOMICS, INC.	-12.61%	1.81B
FLEURY S.A.	-19.01%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.21B
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.11B

Medical & Diagnostic Laboratories